drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous neoantigen-targeted T cell therapy: ex vivo expanded patient PBMC-derived cytotoxic T cells (primarily CD8+) specific to personalized tumor neoantigens; mediate TCR-dependent recognition of neoantigen–HLA class I on tumor cells and kill via perforin/granzyme.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
TCR SELECTED T CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous PBMC-derived cytotoxic T cells (primarily CD8+) are ex vivo expanded and selected for specificity to patient-specific tumor neoantigens. These unengineered T cells use their endogenous TCRs to recognize neoantigen peptides presented on HLA class I on tumor cells, leading to targeted killing via perforin/granzyme-mediated cytolysis.
drug_name
Neo-T
nct_id_drug_ref
NCT05798533